Pharmaceutical Market Europe • September 2023 • 38-40
APPOINTMENTS
Pfizer
Mikael Dolsten
Pfizer has appointed Mikael Dolsten as chief scientific officer and president, Pfizer research and development. Dolsten brings over two decades worth of experience in the pharmaceutical industry and has held a variety of senior positions. Prior to his appointment, Dolsten joined Pfizer, where he served as president of worldwide R&D for over a decade. In this role, he was responsible for the research and development of all compounds with proof of concept (POC) for all therapeutic areas and provided support to post-POC medicine studies. Before joining Pfizer, Dolsten served as president of Wyeth Research, where he led scientists involved in R&D and medical activities across the US, Europe and Asia. Earlier in his career, Dolsten served as executive vice president and head of pharmaceutical research at Boehringer Ingelheim and also global vice president of cardiovascular, metabolism and gastrointestinal at AstraZeneca.
Trinity Life Sciences
Leslie Orne
Trinity Life Sciences has appointed Leslie Orne as chief executive officer. Orne brings more than two decades worth of leadership experience consulting in the life sciences industry to the role. Since 2001, Orne has overseen the delivery of integrated consulting, insights and analytics services to Trinity’s clients. She most recently held the position of senior partner and chief client officer at Trinity.
Destiny Pharma
Chris Tovey
Destiny Pharma has appointed Chris Tovey as chief executive officer. Tovey brings over a decade of experience in leadership roles and currently serves as chief operating officer at Jazz Pharmaceuticals. Prior to this, Tovey served as chief operating officer at GW Pharmaceuticals and he was also vice president and head of global marketing operations at UCB Pharma.
Oncopeptides
Sofia Heigis
Oncopeptides has appointed Sofia Heigis as chief executive officer. Heigis steps into her new role from her previous position at the company, serving as managing director, Germany. Prior to joining Oncopeptides, Heigis worked at AstraAzeneca for over a decade in a variety of positions, including medical affairs director and later vice president of medical and regulatory affairs.
Neumora Therapeutics
Henry Gosebruch
Neumora Therapeutics has appointed Henry Gosebruch as president and chief executive officer. Prior to joining Neumora, Gosebruch served as executive vice president and chief strategy officer at AbbieVie for nearly a decade. Earlier in his career, he worked at JP Morgan for over two decades, where he held the position of co-head of M&A North America.
Avacta Group
Shaun Chilton’
Avacta Group has appointed Shaun Chilton to its board as non-executive director. Chilton has held a number of senior and executive commercial positions in the past three decades prior to his appointment. He has worked for several pharmaceutical and pharmaceutical service industries, including Pfizer, Sanofi and Wolters Kluwer Health. He most recently held the position of chief executive officer at Clinigen Group.
LifeArc
Terri Cooper
LifeArc has appointed Terri Cooper to its board of trustees as a non-executive director. Cooper, who has more than 35 years of experience in the life sciences and healthcare industry, worked at Deloitte for over 16 years in various roles, including as vice chair of the firm’s external DEI practice. Cooper currently serves on multiple boards, including as board chair for Verso Biosense.
LifeArc
Sameer Mistry
LifeArc has appointed Sameer Mistry to its board of trustees as a non-executive director. Mistry holds over 18 years of international experience in pharmaceuticals, medical devices and consumer healthcare across multiple disease areas. He is currently global medical lead, early drug development at GSK, and has held senior roles at Johnson & Johnson. Mistry was previously a doctor in the NHS.
LifeArc
Rima Makarem
LifeArc has appointed Rima Makarem as a non-executive director to its board of trustees. Makarem has gained valuable experience in a variety of roles, including director of competitive excellence at GSK in 2003 and non-executive director and audit chair at NHS Haringey in 2007. She currently serves as chair for multiple organisations, including Sue Ryder and Queen Square Private Healthcare.
AstraZeneca
Sharon Barr
AstraZeneca has appointed Sharon Barr as executive vice president, BioPharmaceuticals R&D. Barr holds nearly two decades of experience in the pharmaceutical industry and has held several senior positions. Prior to her appointment, Barr served as senior vice president and head of research and product development for Alexion, AstraZeneca’s rare disease group, for ten years. She was responsible for drug discovery, process development and clinical supply, as well as clinical biomarkers and bioanalytical discovery. Barr has previously led teams spanning translational research, precision medicine and global development. She has held multiple roles, including vice president, head of research, and senior vice president, head of research, data sciences, bioinformatics, and diagnostics at Alexion Pharmaceuticals. Earlier in her career, she also held the position of assistant director, translational and clinical science at Astellas Pharma after joining the company as a senior research investigator.
Pfizer
Chris Boshoff
Pfizer has appointed Chris Boshoff as chief oncology research, development officer and executive vice president. Boshoff has worked for Pfizer for over a decade in several roles, including chief development officer, oncology and, prior to his appointment, chief development officer, oncology and rare disease. Before Pfizer, Boshoff was the founding director of the University College of London Cancer Institute, London.
Pheon Therapeutics
Cyrus Mozayeni
Pheon Therapeutics has appointed Cyrus Mozayeni as chief executive officer. Mozayeni brings over two decades of experience in the biotechnology industry to Pheon. Prior to this, he co-founded and served as chief executive officer at Vedere Bio through its sale to Novartis. Earlier in his career, he served as co-founder, president and chief business officer at Oncorus.
The King’s Fund
Sarah Woolnough
The King’s Fund has appointed Sarah Woolnough as chief executive officer. Woolnough has held several senior leadership positions across the health and care sector and currently serves as chief executive officer at Asthma + Lung UK. Prior to this, Woolnough held several positions, including director of policy and executive director of policy and information at Cancer Research UK, for over a decade.
Chiesi Group
Maria Paola Chiesi
Chiesi Group has appointed Maria Paola Chiesi as vice chair. Chiesi joined the company nearly two decades ago and has served as corporate social responsibility director. She created and led the shared value and sustainability department and has the responsibility of implementing improvement plans. Alongside her role at Chiesi Group, Paola currently serves as president of the Chiesi Foundation.
IO Biotech
Qasim Ahmad
IO Biotech has appointed Qasim Ahmad as chief medical officer. Ahmad brings over two decades of strategic clinical development, medical affairs and marketing authorisation expertise and most recently served as senior vice president and head of oncology clinical development, medical affairs, US, at Novartis. Prior to this, Ahmad held the position of global medical director at Eli Lilly and Company.
British Heart Foundation
Bryan Williams
The British Heart Foundation has appointed Bryan Williams as chief scientific and medical officer. Williams currently served as chair of medicine at University College London for the past decade. He most recently served as president of the International Society of Hypertension. Earlier in his career, he served as director of research at the University College London Hospitals NHS Foundation Trust.
AC Immune
Nuno Mendonça
AC Immune has appointed Nuno Mendonça as chief medical officer. Prior to his appointment, Mendonça served as senior vice president and chief medical officer of Bial, Portugal. He has also previously held a number of senior positions including senior medical director at Novartis and AveXis. Earlier in his career, he served as medical director at AbbVie.
Bicara Therapeutics
David Raben
Bicara Therapeutics has appointed David Raben as chief medical officer. Raben joins Bicara with over two decades of biopharmaceutical and academic translational oncology experience. Prior to his appointment, he served as vice president of global product development and product general manager, oncology, at Amgen. Prior to Amgen, Raben served as vice president and franchise leader, clinical development oncology, at Genentech.
Research Partnership
Sue Wild
Research Partnership has appointed Sue Wild as president, US pharma. Wild joins the company from Ipsos, where she served as executive vice president and sector lead for its US Qualitative Healthcare business. She also previously led the firm's Global Healthcare Qualitative Center of Excellence. Prior to that, Wild worked in a variety of roles within GfK's healthcare division,
including as senior vice president.
Fishawack Health
Celine Vita
Fishawack Health has appointed Celine Vita as chief growth officer. Vita brings over 25 years of leadership and business transformation experience to the role and joins the agency from Centron, where she served as president. Prior to this, Vita was at CDM New York for 16 years, rising through the ranks from senior account executive to associate partner and director of business growth.
GCI Health
Marley Glabman
GCI Health has appointed Marley Glabman as vice president, digital influencer. Glabman has more than eight years of experience within the entertainment industry and
joins the agency from Edelman, where she served as director, influencer marketing. Prior to this, Glabman worked at Starpower as a senior account executive, entertainment marketing, and as a senior account executive at dOMAIN Integrated.
Onyx Health
Sarah Seilly
Onyx Health has appointed Sarah Seilly as head of medical education. Seilly brings extensive industry experience to the role and joins from Olympus Medical, where she most recently served as lead clinical education specialist. Prior to this, Seilly worked in several roles for over a decade at Covidien, most recently as clinical education manager. She was also previously a nurse advisor in the field of urology.
The Considered
Tina Bertolini
The Considered has appointed Tina Bertolini as head of operations and project management. Bertolini has been with the agency since its beginnings in 2021, first as senior operations manager and then as director of operations and project management. Prior to this, Bertolini served as senior project manager at global creative agency Rapp. She also held roles at DBB earlier in her career.
Porterhouse Insights
Ann-Marie Mulhall
Porterhouse Insights has appointed Ann-Marie Mulhall as account director. Mulhall, a qualitative and quantitative research professional, has seven years of healthcare research agency experience and joins from her most recent role as account director at Lumanity. Prior to this, Mulhall was a qualitative and quantitative researcher at Research Partnership and also previously worked as a clinical data scientist at GSK.
Research Partnership
Tom Donnelly
Research Partnership has appointed Tom Donnelly as a director in the US MedTech division. Donnelly, who carries nearly two decades' worth of experience in healthcare insights, joins from Branding Science, where he served as vice president, MedTech. Prior to this, Donnelly was vice president of MarketVision Research. He also leads Intellus Worldwide's Clear Health Communications Committee.
GCI Health
Olivia Randolph
GCI Health has appointed Olivia Randolph as senior HR coordinator. Randolph joins the agency from US financial technology platform Current, where she most recently held the position of human resources coordinator, after originally joining as an office assistant. Prior to this, Randolph worked as an e-commerce fulfilment manager at Keni Tana. She also previously served as a staff writer.
90TEN
Tracey McManus
90TEN has appointed Tracey McManus as senior medical writer. McManus brings extensive experience in medical communications and an academic background in neuroscience to the role. She joins 90TEN from Envision Pharma Group, where she served as a senior medical writer. Prior to this, McManus worked as a senior medical writer at Ashfield Medcomms for nearly nine years.
GCI Health
Maya Schioppo
GCI Health has appointed Maya Schioppo as operations coordinator. Schioppo joins the agency from her most recent role as assistant account executive at Hill+Knowlton Strategies. Prior to this, she worked freelance in public relations, beauty for Alison Brod Marketing and Communications after completing an internship at the agency. Schioppo also previously undertook an internship in social media and communications.
GCI Health
Connor Silverstein
GCI Health has appointed Connor Silverstein as account coordinator. Alongside his new role, Silverstein also serves as chief technology officer at volunteer-based non-profit organisation United Women of Rockland. He joins GCI Health from his most recent marketing at BHG Financial, where he served as brand coordinator after first joining the company as a social media intern.
SAY
Ben Palmer
SAY has appointed Ben Palmer as junior account executive. Palmer has a background in biology and social media, and brings a passion for science to the role, as well as an interest in the life sciences communications industry. He most recently served as an editorial assistant at Faculty Opinions. Prior to this, he completed an internship at Bright Network.
Pharmaceutical Market Europe (PME)
Pharmaceutical industry news, articles, jobs, reports, advice and services